Fig. 1: Functional and anatomic outcomes in patients with nAMD at Week 8 in SPECTRUM.

A Mean change in VA from baseline at Week 8. B Mean change in CRT from baseline at Week 8. C Proportion of patients without intraretinal fluid or subretinal fluid at Week 8. Data are for the FAS (observed cases); error bars represent 95% CI. Mean VA/CRT change at Week 4 and Week 8 from baseline was calculated in patients with a VA/CRT assessment at Week 4 and Week 8, respectively. Week 4 = visits closest to 28 (14–42) days after the first injection (BL), and Week 8 = visits closest to 56 (43–70) days after BL. Note that outcomes described here would not reflect the effect of an injection received at Week 8, and some patients may not have received an injection at this timepoint. BL baseline, CRT central retinal thickness, ETDRS Early Treatment Diabetic Retinopathy Study, FAS full analysis set (all patients receiving ≥1 dose of study drug plus ≥1 post-baseline assessment), nAMD neovascular age-related macular degeneration, PT previously treated, TN treatment-naïve, VA visual acuity, W week. ^aFluid data were collected per investigator discretion; the presence of intraretinal fluid and subretinal fluid was determined by optical coherence tomography with the instrument available at each study site, and the proportions presented here were calculated based on the number of patients who had an assessment at each of the indicated timepoints.